Needham analyst Gerald Pascarelli has maintained a Buy rating on Philip Morris Intl and raised the price target to $215 from the previous $200. The revised target suggests increased confidence in the company's valuation and future performance.

Rating and Price Action

The decision to upgrade the price target comes as the firm evaluates Philip Morris Intl's current market position. The stock continues to trade on the NYSE under the ticker PM.

Philip Morris International Inc. reported financial results for the second quarter of 2026 on July 22, 2026, achieving net revenues of $11.192 billion, an increase of 10.4% reported and 7.6% organically. This growth was driven by strong performance across its smoke-free and combustibles segments, with adjusted diluted EPS growing by 15.2% to $2.20, beating the analyst consensus estimate of $2.04. Reported diluted EPS was $1.80, impacted by a $511 million noncash impairment charge related to PMI's investment in RBH.

Second-Quarter 2026 Performance Highlights

The company's smoke-free business accounted for approximately 42% of total net revenues, up by 0.5 percentage points versus the prior year. Total shipment volume increased by 2.5% to 205.2 billion equivalent units, with smoke-free shipments rising by 7.5% and cigarette volume increasing by 1.1%. Gross profit increased by 11.5% reported and 8.7% organically to $7.7 billion, while operating income rose by 22.0% reported and 10.7% organically to $4.5 billion. Adjusted operating margin expanded to 42.6% from 41.9%.

Segment Performance

The International Smoke-Free segment continued to drive growth, with net revenue increasing by 14.2% reported and 11.8% organically to $3.88 billion. IQOS adjusted in-market sales rose 5.1%, or 10% excluding Japan and Poland. VEEV shipments surged 55.1%, while international modern oral product volumes increased 14.7%. The International Combustibles segment saw net revenues grow by 9.8% reported and 6.4% organically to $6.46 billion, supported by 10% pricing growth. In the U.S. segment, net revenues declined by 0.7% reported to $856 million, reflecting declines in cigars and unfavorable phasing in Wellness, alongside broadly stable revenues for ZYN.

Strategic Outlook and Guidance

Philip Morris International updated its full-year 2026 forecast for reported diluted EPS to a range of $7.19 to $7.34, raised from $7.18-$7.33. Excluding adjustments totaling $1.07 per share, the company projects adjusted diluted EPS to increase by 9.5% to 11.5% versus 2025, though it lowered its adjusted EPS outlook to $8.26-$8.41 from $8.31-$8.46. The company expects third-quarter adjusted EPS of $2.20-$2.25. PMI maintained its guidance for 5%-7% organic revenue growth and 7%-9% organic operating income growth. Management indicated plans to step up investment in the U.S. market for the ZYN brand in the second half of 2026, including new product launches such as ZYN Ultra.